European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphoma

Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that typically becomes harder to treat each time a patient relapses1,2Lunsumio subcutaneous offers a new treatment option that can significantly reduce administration time to approximately one minuteAvailability of Lunsumio SC allows patients to receive treatment aligned to clinical requirements and lifestyle preferences Basel, 19 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ...